Question-and-Answer Session
Operator
(Operator Instructions) Your first question comes from Liana Moussatos of Wedbush Morgan.
Liana Moussatos - Wedbush Morgan
Could you repeat the quarter-over-quarter AzaSite sales and prescription growth and then what was the stock based compensation amount? Also, how many potential partners are in discussion for x North America commercialization of denufosol and then finally could you go into a little more detail on what we can expect from Restasis and Elestat longer-term from like 2010 on?
Tom Staab
As far as AzaSite performance revenues increased 54% and prescriptions increased 29% when you compare them to Q3 levels. Then I did not get all of your questions.
Liana Moussatos - Wedbush Morgan
What was the fourth quarter stock based compensation amount?
Tom Staab
I don’t have that number off the top of my head, but total stock based comp for 2008 was between $4 and $5 million. It is roughly the same between the quarters.
Liana Moussatos - Wedbush Morgan
Okay and how many potential partners are you currently in discussion with for the commercialization of denufosol outside of North America?
Tom Staab
I would prefer not to comment about the number of partners. I can tell you that we are pleased with the way things have gone and that we hope to update everybody on partnering discussions in the future.
Liana Moussatos - Wedbush Morgan
Is there more than one?
Tom Staab
I can’t comment on that, I’m sorry.
Liana Moussatos - Wedbush Morgan
Okay and then my last question is can you kind of describe to us what you would expect from Restasis and Elestat especially from 2010 on? Do we just take Elestat out of our models?
Tom Staab
Well what I can tell you and we have only provided 2009 guidance because obviously there is lot of information that could come down the pike in 2009, so we’d like to limit guidance that we feel most comfortable and so we just limit it to 2009.
I can tell you from an Elestat prospective we have spent a considerable amount of time looking at that situation and the best guidance I can give you is that we think that it’s unlikely that a generic epinastine product will be launched in 2009. I looked at the timeline; the most likely timeline is one to two years from now.
Liana Moussatos - Wedbush Morgan
Would you consider selling Elestat as a generic?
- To read the full transcript on Seeking Alpha, click here »
